GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aurora Spine Corp (TSXV:ASG) » Definitions » EV-to-FCF

Aurora Spine (TSXV:ASG) EV-to-FCF : -16.62 (As of May. 31, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Aurora Spine EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aurora Spine's Enterprise Value is C$23.08 Mil. Aurora Spine's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.39 Mil. Therefore, Aurora Spine's EV-to-FCF for today is -16.62.

The historical rank and industry rank for Aurora Spine's EV-to-FCF or its related term are showing as below:

TSXV:ASG' s EV-to-FCF Range Over the Past 10 Years
Min: -358.15   Med: -5.37   Max: 736.39
Current: -16.33

During the past 11 years, the highest EV-to-FCF of Aurora Spine was 736.39. The lowest was -358.15. And the median was -5.37.

TSXV:ASG's EV-to-FCF is ranked worse than
100% of 361 companies
in the Medical Devices & Instruments industry
Industry Median: 26.94 vs TSXV:ASG: -16.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-31), Aurora Spine's stock price is C$0.24. Aurora Spine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.023. Therefore, Aurora Spine's PE Ratio for today is At Loss.


Aurora Spine EV-to-FCF Historical Data

The historical data trend for Aurora Spine's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurora Spine EV-to-FCF Chart

Aurora Spine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.39 -73.24 -6.12 -10.28 -18.36

Aurora Spine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.42 -20.66 -27.46 -18.36 -25.23

Competitive Comparison of Aurora Spine's EV-to-FCF

For the Medical Devices subindustry, Aurora Spine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurora Spine's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aurora Spine's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Aurora Spine's EV-to-FCF falls into.



Aurora Spine EV-to-FCF Calculation

Aurora Spine's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=23.082/-1.389
=-16.62

Aurora Spine's current Enterprise Value is C$23.08 Mil.
Aurora Spine's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurora Spine  (TSXV:ASG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Aurora Spine's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.24/-0.023
=At Loss

Aurora Spine's share price for today is C$0.24.
Aurora Spine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.023.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Aurora Spine EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Aurora Spine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurora Spine (TSXV:ASG) Business Description

Traded in Other Exchanges
Address
20 Holly Street, Suite 300, Toronto, ON, CAN, M4S 3B1
Aurora Spine Corp is engaged in the business of the development and commercialization of minimally invasive interspinous fusion systems and devices. The product portfolio includes implants, surgical tools, and biologics. It derives revenues primarily from the sale of spinal surgery implants, consumable products used in spinal surgeries, and service revenue for referring products to its customers.
Executives
James Snow Director